PureTech Health plc (PRTC)
NASDAQ: PRTC · Real-Time Price · USD
15.51
-0.57 (-3.54%)
Sep 15, 2025, 4:00 PM EDT - Market closed
PureTech Health Revenue
PureTech Health had revenue of $1.85M in the half year ending June 30, 2025, a decrease of -41.24%. This brings the company's revenue in the last twelve months to $6.39M, up 1,265.60% year-over-year. In the year 2024, PureTech Health had annual revenue of $4.83M with 44.98% growth.
Revenue (ttm)
$6.39M
Revenue Growth
+1,265.60%
P/S Ratio
57.81
Revenue / Employee
$114,125
Employees
56
Market Cap
369.43M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.83M | 1.50M | 44.98% |
Dec 31, 2023 | 3.33M | -12.29M | -78.68% |
Dec 31, 2022 | 15.62M | -1.77M | -10.18% |
Dec 31, 2021 | 17.39M | 5.62M | 47.76% |
Dec 31, 2020 | 11.77M | 1.96M | 20.00% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PRTC News
- 18 days ago - PureTech Health plc (PRTC) Q2 2025 Earnings Conference Call Transcript - Seeking Alpha
- 18 days ago - PureTech Health plc – Half-Year Report - Business Wire
- 25 days ago - PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF - Business Wire
- 4 weeks ago - PureTech Health: Notice of Half-Yearly Results - Business Wire
- 4 weeks ago - PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint - Business Wire
- 4 weeks ago - PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases - Business Wire
- 2 months ago - PureTech Announces Leadership Transition - Business Wire
- 2 months ago - PureTech Announces Board Change - Business Wire